Indeed, some have argued that APOE has no influence on cognition in mid- or late-life beyond increasing risk for AD, such that effects found on cognition reflect the decades of a pre-symptomatic period of AD pathology (e.g. Vemuri et al., 2010; see also O’Donoghue et al., 2018). This evidence concerns the gene APOE and Alzheimer disease.